Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

From the analyst's couch: The outlook for biotech exits

The spectacular performance of biopharma companies in the public markets last year has carried over into optimism for early 2014. Will the boom continue?

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Stage of development of biopharma IPOs.
Figure 2: Stage of development of acquired companies in 2008–2012.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Annette Grimaldi.

Ethics declarations

Competing interests

Annette Grimaldi is a managing director at BMO Capital Markets in New York.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Grimaldi, A. From the analyst's couch: The outlook for biotech exits. Nat Biotechnol 32, 227–228 (2014). https://doi.org/10.1038/nbt.2852

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2852

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing